Implementation of the Alzheimer’s blood‐based biomarker panel in clinical practice: the development of cutoffs for plasma Abeta1‐42/1‐40, P‐tau181, GFAP and NfL across the clinical continuum

Several blood‐based biomarkers for Alzheimer’s disease (AD) can now be reliably measured. It is not yet clear how those markers should be interpreted in a real‐world clinical setting, where a heterogeneous group of patients presents in different syndromal stages and with different symptoms. We aim to establish a ready‐to‐implement blood‐based biomarker panel including Abeta1‐42/1‐40, P‐tau181, GFAP and NfL with cutoffs for clinical application among subjective cognitive decline (SCD), mild cognitive impairment (MCI), AD‐dementia, frontotemporal dementia (FTD) and dementia with Lewy bodies (DLB).